In the “Selected GBMs” group, a Kaplan-Meier survival analysis was performed on patients with a histopathological diagnosis of glioblastoma, regardless of tumor biology (IDH status or MGMT promoter status), and regardless of subsequent chemoradiation, by extent of resection using the four tiers described above. This evidence concerns the gene IDH2 and neoplasm.